Current Clinical Trials

The Medical Research Center of Connecticut was founded by Gastroenterology Center of Connecticut physicians in 2000. Our mission is to provide high quality care to our patients offering the opportunity to participate in clinical trials involving established and promising new treatments for gastrointestinal and liver disease.

We are currently enrolling participants in the following studies:

Ulcerative Colitis
  • AbbVie Protocol M14-234

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
    More Information

  • AbbVie Risankizumab M16-067

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects
    with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

    More Information

  • Boehringer Ingelheim 1368.5

    A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy
    More Information

  • Seres 201

    A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER 287 in Adults with Active Mild-to-Moderate Ulcerative Colitis

    More Information

Crohn's
  • Abbvie M14-433 (ABT-494)

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy
    More Information

  • BMS

    A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease
    More Information

IBS - Constipation
  • None at this time

IBS - Diarrhea
  • Urovant

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women with Irritable Bowel Syndrome
    More Information

Other Studies
  •  SeraTrials - Protocol 05035

    Prospective Collection of Samples for Research: Objective is to obtain blood and/or biological samples from donors who have or have been screened for a variety of identifying characteristics and associated illness, as well as normal controls

  • Relamorelin-01

    A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    More Information

  • Relamorelin-03

    A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in
    Patients with Diabetic Gastroparesis
    More Information

  • Relamorelin-04

    A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Gastroparesis
    More Information

  • Ironwood

    A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors
    More Information

Registries
  • Legacy Registry P11-282

    A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA®(Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)

  • Entyvio PASS Registry

    Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease.
    More Information

  • ONWARD

    Observational, Real-World Study of Inflectra in patients with IBD
    More Information

  • Corrona

    Corrona Inflammatory Bowel Disease (IBD) Registry
    More Information

C.Diff
  • Seres 012 - ECOSPOR III

    A Phase 3 Multicenter, RandomizeEd, Double-Blind, Placebo-COntrolled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI).
    More Information

  • C.diff Vaccine:  CLOVER

    A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER.
    More Information

  • Rebiotix PUNCH CD3

    A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection.

  • American Gastroenterological Association (AGA) FMT Registry

    A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness.
    More Information

  • Finch

    A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota™ (CP101) in Subjects with Recurrence of Clostridium difficile Infection
    More Information

 

If you are interested in learning more about the Medical Research Center of Connecticut or the studies in which we participate, please contact Jennifer Nikolich, our Research Nurse Administrator, at (203) 281-5161.